July 27, 2022
InCarda Therapeutics Announces Enrollment of First Patient in Pivotal Phase 3 RESTORE-1 Trial of InRhythm™ for the Treatment of Paroxysmal Atrial Fibrillation
Media
July 26, 2022
Precirix and Eckert & Ziegler sign agreement on priority supply of the therapeutic radioisotope Actinium-225
July 26, 2022
Q2 2022 General Market Overview
July 20, 2022
FDA announces an Oncologic Drugs Advisory Committee meeting to discuss benefit/risk profile of Oncopeptides’ Pepaxto
July 15, 2022
BONESUPPORT HOLDING AB (PUBL) – PUBLISHES Q2 2022 INTERIM REPORT
July 15, 2022
Oncopeptides has carried out a directed share issue of approximately SEK 435.6 million (approximately USD 41.1 million)
July 14, 2022
Hemab Therapeutics Presents New Data on HMB-001 for the Treatment of Glanzmann Thrombasthenia and Other Bleeding Disorders at 2022 ISTH Congress
July 07, 2022
BONESUPPORT HOLDING AB (publ) – Invitation to conference call and webcast for Interim Report Q2 2022
July 07, 2022
Ariceum Therapeutics Appoints Chief Business Officer
July 05, 2022
Nordic Nanovector to Discontinue PARADIGME, its Phase 2b Trial with Betalutin[®] in 3L R and R Follicular Lymphoma